MoonLake Immunotherapeutics
MLTX
$17.80
-$0.20-1.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.51M | 9.21M | 10.80M | 10.94M | 11.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.02M | 65.22M | 71.43M | 60.70M | 47.49M |
| Operating Income | -70.02M | -65.22M | -71.43M | -60.70M | -47.49M |
| Income Before Tax | -69.09M | -62.77M | -70.58M | -55.96M | -40.41M |
| Income Tax Expenses | 622.00K | 248.00K | 115.00K | 95.00K | 153.00K |
| Earnings from Continuing Operations | -69.71M | -63.02M | -70.69M | -56.05M | -40.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 591.00K | 965.00K | 831.00K | 615.00K |
| Net Income | -69.71M | -62.43M | -69.73M | -55.22M | -39.94M |
| EBIT | -70.02M | -65.22M | -71.43M | -60.70M | -47.49M |
| EBITDA | -69.18M | -64.47M | -70.69M | -59.96M | -47.11M |
| EPS Basic | -0.98 | -0.92 | -1.10 | -0.87 | -0.63 |
| Normalized Basic EPS | -0.61 | -0.57 | -0.68 | -0.54 | -0.39 |
| EPS Diluted | -0.98 | -0.92 | -1.10 | -0.87 | -0.63 |
| Normalized Diluted EPS | -0.61 | -0.57 | -0.68 | -0.54 | -0.39 |
| Average Basic Shares Outstanding | 71.27M | 67.97M | 63.37M | 63.28M | 63.23M |
| Average Diluted Shares Outstanding | 71.27M | 67.97M | 63.37M | 63.28M | 63.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |